Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Francis Obeng

Internal Medicine Charlotte, NC Medical Doctor

NPI 1902866601 CMS profile 268306

2540 W Arrowood Rd Ste 110, Charlotte, NC 28273

Open in the dashboard

General payments

$8,801

482 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Francis Obeng of Charlotte, NC is reported in the CMS Open Payments database as having received $8,801 across 482 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,243 98
2024 General $1,674 84
2023 General $1,299 74
2022 General $544 26
2021 General $147 10
2020 General $811 54
2019 General $2,084 136

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Francis Obeng
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Francis Obeng were reported at $2,243. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Francis Obeng Internal Medicine median Middle half National median
2019 $2,084 $159 $48–$570 $163
2020 $811 $119 $33–$402 $114
2021 $147 $135 $37–$521 $132
2022 $544 $141 $42–$496 $149
2023 $1,299 $149 $45–$519 $160
2024 $1,674 $154 $47–$537 $164
2025 $2,243 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,668 88 payments
  2. Novo Nordisk Inc $1,662 98 payments
  3. AbbVie, Inc. $717 31 payments
  4. Sanofi-Aventis U.S. LLC $522 20 payments
  5. Lilly USA, LLC $521 31 payments
  6. Pfizer Inc. $512 34 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $290 14 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $237 13 payments
  9. Amgen Inc. $221 13 payments
  10. Kowa Pharmaceuticals America, Inc. $211 15 payments
  11. Other $2,237 125 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,598 478 payments
  2. Gift $119 2 payments
  3. Education $83 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,029 63 payments
  2. Ozempic $693 47 payments
  3. RYBELSUS $596 36 payments
  4. UBRELVY $589 25 payments
  5. Wegovy $433 19 payments
  6. QULIPTA $429 17 payments
  7. BREZTRI $285 9 payments
  8. NURTEC ODT $262 16 payments
  9. ZAVZPRET $262 16 payments
  10. AIRSUPRA $239 8 payments
  11. Other $6,475 382 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 159 drugs

Part D claims

9,358

Median for Internal Medicine: 777

Drug cost

$1,227,539

Median for Internal Medicine: $73,373

Branded share of claims

22.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 182 $259,599
Januvia Sitagliptin Phosphate Brand 90 $110,687
Rybelsus Semaglutide Brand 59 $79,721
Eliquis Apixaban Brand 77 $78,762
Jardiance Empagliflozin Brand 43 $70,827
Trulicity Dulaglutide Brand 51 $68,885
Mounjaro Tirzepatide Brand 55 $68,824
Tresiba Flextouch U-200 Insulin Degludec Brand 44 $48,328
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 64 $47,754
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 26 $43,559

The 10 drugs with the highest cost, of 159 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$86,108

Of which drugs: $2,905

Medicare patients

253

Average age 74

Services billed

7,632

147 women, 106 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 46%
Arthritis 35%
Ischemic heart disease 32%
Chronic kidney disease 30%
Heart failure 29%
Depression 24%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 15 15 $1,227
Injection, methylprednisolone acetate, 1 mg J1010 Office 32 5,203 $515
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 43 115 $90
Injection, methylprednisolone acetate, 80 mg J1040 Office 19 22 $73
Injection, ketorolac tromethamine, per 15 mg J1885 Office 30 78 $36

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $183
$183 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $150
$150 28 —
Ozempic
  • Novo Nordisk Inc $113
$113 182 —
QULIPTA
  • AbbVie, Inc. $94
$94 — —
RYBELSUS
  • Novo Nordisk Inc $88
$88 59 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

482 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record